Photo from wikipedia
Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published… Click to show full abstract
Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition of abiraterone acetate plus prednisone to ADT has a clear survival benefit and acceptable overall tolerance, and should be considered as another standard of care for newly diagnosed mHSPC.
Keywords:
abiraterone acetate;
prostate cancer;
hormone sensitive;
metastatic hormone;
another standard;
sensitive prostate
Journal Title: European urology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European urology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!